MoneyWorks4Me

USFDA classifies Cipla’s Bengaluru manufacturing facility as Voluntary Action Indicated

10 Feb 2025 Evaluate

United States Food and Drugs Administration (USFDA) has classified routine current Good Manufacturing Practices (cGMP) inspection conducted at Cipla’s Bengaluru manufacturing facility, as Voluntary Action Indicated (VAI). USFDA had conducted routine current Good Manufacturing Practices inspection at Cipla’s said facility from November 07 to November 13, 2024. 

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Peers
Company Name CMP
Sun Pharma. Inds. 1865.00
Dr. Reddys Labs. 1210.10
Cipla 1380.00
Lupin 2100.00
Zydus Lifesciences 1169.50
View more..